“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute (PRI), are working in collaboration within the ‘Intestinal Microbiome-based Medicines European Task Group (IMM-ETG)’ to propose a harmonised, pan-European, regulatory approach to intestinal microbiome whole ecosystem[1]-based therapeutics”
Monday, 20 May 2019 – Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma which are developing drugs from the microbiome whole ecosystem, in coordination with the PRI, have established a joint collaboration focused on creating a proposal with recommendations for a common European regulatory framework for human intestinal microbiome whole ecosystem-based therapeutics.
Through this new collaboration, IMM-ETG hopes to gain valuable insight and feedback from the competent authorities with the aim of establishing a harmonised regulatory landscape for such products across the European Union.
The key objectives of IMM-ETG are:
– Support translational research and commercial drug development by building a harmonised regulatory framework for manipulated intestinal microbiome whole ecosystem-based products.
– Obtain a universally accepted product classification for these products.
– Facilitate communication with key stakeholders, including policy makers, regulatory agencies, academic groups, clinicians and microbiome therapeutic companies.
CONTEXT
Currently, the regulation and classification of Faecal Microbiota for Transplantation in Member States of the European Union falls within the remit of each respective national competent authority[2] and, as such, there is no clearly-defined pan-European harmonised regulatory pathway for companies pursuing industrially produced intestinal microbiome whole ecosystem-based therapeutics.
Most of the 30+ active clinical trials (using Faecal Microbiota Transplantation) in Europe are mainly sponsored by academics and are regulated on a national basis. As the industry develops there is a strong need for regulatory harmonisation and clarity across Europe in this domain.
This collaborative effort by IMM-ETG is focused on developing a number of regulatory suggestions, proposals and recommendations in relation to intestinal microbiome whole ecosystem-derived drug development across the various categories of industrially-produced medicinal products.
EMPIRICAL FAECAL MICROBIOTA TRANSPLANTATION (FMT)
Faecal Microbiota Transplantation (FMT) is a medical procedure that has emerged as an effective treatment option for various severe, microbial infections including recurrent and refractory Clostridium difficile. In this context, the Faecal Microbiota that is administered is regulated as a drug in several countries (i.e. France, Germany, United Kingdom, United States, Canada, Switzerland). This largely non-standardised[3] treatment works by introducing intestinal microbiota from the faeces of a donor into the gut of a recipient with the intention of treating a disease. The key steps of the process[4] are: the screening of donors, the collection of a donation, dilution of the donation with sterile saline solution (0.9%) and, usually, the addition of glycerol (10%) when frozen.
Faecal Microbiota is a heterogeneous and complicated consortium of microorganisms (bacterial, viruses and fungi), human cells and undigested food substances. The EU commission has previously released a position which stated that when administered into a recipient with therapeutic intention, the ‘active components’ of the faecal microbiota are not the human cells. In light of this, Faecal Microbiota is not considered as falling within the scope of Directive 2004/23/EC[5] on human tissues and cells legislation, and may be considered as a medicinal product.
The IMM-ETG endorses and encourages academic research using FMT and is open to collaborate in this field. In this context it should be emphasized that, according to the Directive 2001/83/EC, Title II, Article 3: ‘medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient (commonly known as the magistral formula)’[6] does not fall under its scope and can be regulated at the national level, under a hospital pharmacy exemption. Faecal Microbiota material intended to be transferred into an individual recipient, as described previously, enters in this definition and therefore, doesn’t fall under the scope of the Directive 2001/83/EC.
The IMM-ETG is of the view that for empirical FMT using Faecal Microbiota prepared under hospital pharmacy exemption, it is generally acceptable that there is limited quality control of the final product against specific release criteria or analysis of the final composition for comparison with initial donor microbiota. These are key differences between products prepared industrially by a method involving a standardised and reproducible industrial process. Furthermore by definition, these hospital pharmacy-prepared products can only be on a small scale for individual patients and are not allowed to be commercialised.
INTESTINAL MICROBIOME MEDICINAL PRODUCT (IMMP)
The IMM-ETG position is that intestinal microbiome whole ecosystem-derived products that are prepared outside the hospital pharmacy exemption should be regulated as a medicinal product following industry standards and controlled in such a way that a product of consistent batch-to-batch quality is available to patients. Individual intestinal microbiome whole ecosystem derived-products need to be classified as particular types of medicinal products.
The IMM-ETG proposes that products defined as intestinal microbiome whole ecosystem-derived (collected from an appropriately screened single donor, pool of donors or from the recipient themselves) are medicinal products, in so far as they are intended to ‘treat or prevent disease in human beings’[7] and are to be regulated according to Directive 2001/83/EC across all EU Member States, as long as they are ‘intended to be placed on the market in Member States and either prepared industrially or manufactured by a method involving an industrial process’ [8].
Practice across the developed world is that industrially-produced intestinal medicinal products should be standardised, manufactured and controlled with validated and reproducible processes and released according to the principles of Good Manufacturing Practice (GMP) under a license from a competent authority. In line with this, the group is of the view that all intestinal microbiome whole ecosystem-derived medicinal products that are industrially produced need to be manufactured in a GMP-licensed facility. Furthermore, such products intended for use in a clinical trial should also be subject to the pertinent quality and GMP requirements for all medicinal products.
ABOUT MICROBIOME THERAPEUTICS COMPANIES
Caelus Health is an Amsterdam-based biotech company developing an entirely new class of Microbiome Therapeutics with an initial focus on the increase of insulin sensitivity and prevention of Type 2 Diabetes (T2DM) in people with metabolic syndrome.
The company is dedicated to the commercialization of functional food and pharmabiotic products for the prevention and early treatment of cardio-metabolic diseases – based on the strong correlation between the intestinal microbiome and health.
Caelus Health builds on the experience of leading scientists in this field and is dedicated to effectively capture the value of Microbiome Therapeutics through solid preclinical and early-stage clinical development approaches.
EnteroBiotix is leveraging the untapped potential of the human microbiome for the benefit of patients by developing novel medicinal products that restore health and prevent disease, with an initial focus on drug-resistant bacterial infections and gastrointestinal conditions.
The Company has established fully integrated ISO:9001/2008 collection and GMP-compliant clean room manufacturing capabilities under a ‘specials’ license from the Medicines and Healthcare Products Regulatory Agency (MHRA).
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
In 2018, Ferring acquired Rebiotix Inc., which is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionise the treatment of challenging diseases. Rebiotix possesses a deep and diverse clinical pipeline targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ (MRT™) drug platform. The MRT platform is a standardised, stabilised drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit rebiotix.
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
About the Pharmabiotic Research Institute (PRI)
The Pharmabiotic Research Institute (PRI) is a European independent non-profit group which works on behalf of its members to help them clarify and propose regulatory guidelines and standards for the development of new medicines and therapies based in the Human Microbiome for the European market. They do this by applying a unique collaborative approach in collecting and researching the regulatory and technical issues which exist in developing these products. The PRI was created in 2010, and today counts over 80 members.
